dQ&A launched the beta of our next-gen AI Insights Platform—a breakthrough natural language solution providing instant, data-driven answers for the diabetes market.
Our second COVID-19 impact survey of 4,500+ U.S. diabetes patients found ongoing drug/supply delays, care disruptions, and declines in diet and exercise.
Our study of US patients explores insulin rationing’s physical & emotional impact through qualitative & quantitative research. Check out the community video.
A recent patient-reported outcome (PRO) measurement found that reduced hypoglycemia awareness is common in both type 1 and type 2 diabetes.
This survey explores the impact of COVID-19 on diabetes management, revealing high concern, precautionary steps, and changes in work and daily routines.
Part 1 of dQ&A’s CGM Series charts the rapid global rise of continuous glucose monitoring (CGM) —why uptake is soaring, benefits for patients, and what’s next.
Discover how self-recorded “diabetes diary” videos can provide researchers truer patient voices than in-person research.
Our 10-year member journeys reveal a powerful window into the diabetes patient experience, showing advances and the challenges that still remain.
dQ&A helps clients include robust patient-preference studies in FDA regulatory submissions, strengthening decisions that shape diabetes care.
